Tealwood Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Tealwood Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$991K	Sell	17,324 -678	-4%	-$37.1K	0.38%	112
2026 Q1	$1.02M	Sell	18,002 -157	-0.9%	-$9.15K	0.46%	105
2025 Q4	$1.08M	Sell	18,159 -2,582	-12%	-$141K	0.48%	101
2025 Q3	$1.12M	Sell	20,741 -822	-4%	-$47K	0.45%	105
2025 Q2	$1.19M	Buy	21,563 +5,874	+37%	+$346K	0.53%	102
2025 Q1	$1.11M	Buy	15,689 +156	+1%	+$10.5K	0.51%	99
2024 Q4	$1.02M	Sell	15,533 -117	-0.7%	-$7.84K	0.42%	111
2024 Q3	$1.1M	Buy	15,650 +3,503	+29%	+$293K	0.48%	111
2024 Q2	$1M	Sell	12,147 -54	-0.4%	-$4.5K	0.6%	84
2024 Q1	$1.07M	Sell	12,201 -225	-2%	-$20.1K	0.48%	108
2023 Q4	$1.2M	Sell	12,426 -323	-3%	-$28.6K	0.57%	91
2023 Q3	$1.13M	Sell	12,749 -274	-2%	-$24.4K	0.58%	89
2023 Q2	$1.13M	Sell	13,023 -233	-2%	-$21.9K	0.55%	98
2023 Q1	$1.29M	Sell	13,256 -157	-1%	-$16.3K	0.66%	70
2022 Q4	$1.39M	Sell	13,413 -1,146	-8%	-$108K	0.73%	59
2022 Q3	$1.23M	Sell	14,559 -43	-0.3%	-$3.83K	0.67%	64
2022 Q2	$1.21M	Sell	14,602 -368	-2%	-$29.3K	0.6%	76
2022 Q1	$1.15M	Sell	14,970 -244	-2%	-$20.4K	0.49%	106
2021 Q4	$1.34M	Buy	+15,214	New	+$1.26M	0.54%	92

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Tealwood Asset Management's BMRN Position: Q2 2026 in Review

Tealwood Asset Management reduced its BioMarin Pharmaceuticals (BMRN) stake by 3.8% in Q2 2026, selling an estimated $37.1K and leaving 17,324 shares worth $991K. The position accounts for 0.38% of the portfolio, ranked #112.

Tealwood Asset Management first reported a position in BMRN in Q4 2021 and has held it in 19 quarters since. The position peaked at $1.39M in Q4 2022. 562 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Tealwood Asset Management held 17,324 shares of BioMarin Pharmaceuticals worth $991K as of Q2 2026.
Tealwood Asset Management sold 678 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $37.1K.
BioMarin Pharmaceuticals made up 0.38% of Tealwood Asset Management's portfolio in Q2 2026, its #112 holding.
Tealwood Asset Management first reported a position in BioMarin Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
Tealwood Asset Management's BioMarin Pharmaceuticals position peaked at $1.39M in Q4 2022.
562 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Tealwood Asset Management's 13F filing for Q2 2026, filed 14 Jul 2026.